You had previously indicated interest in an OAB study with UBC. We are contacting you to inquire about your interest in another OAB opportunity.
This is a Multi-center, double-blind, parallel-group, randomized placebo-controlled, Phase III study of an intravesical study drug given as a single dose in patients with Idiopathic Overactive Bladder. Post instillation, at 12 weeks, all blinded subjects (active or placebo) will have the option of an additional instillation of study drug. All subjects will be followed up for 24 weeks after their initial instillation.
Study Population:
Male and non-pregnant, non-lactating non-postpartum (1 year) female OAB patient 18 years of age and older with symptoms of urinary urgency and increased daytime frequency with or without urinary urgency incontinence and nocturia, who have had inadequate response or limiting side effects with oral therapy for the treatment of OAB and who meet all of the inclusion and exclusion criteria.